Header Logo

Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Peter Friedmann and Elizabeth Evans.
Connection Strength

4.968
  1. Evans EA, Pivovarova E, Senthilkumar R, Rottapel RE, Stopka TJ, Santelices C, Ferguson WJ, Friedmann PD. Diversion of medications to treat opioid use disorder: Qualitative findings from formerly incarcerated adults in Massachusetts. Int J Drug Policy. 2023 Dec; 122:104252.
    View in: PubMed
    Score: 0.961
  2. Friedmann PD, Dunn D, Michener P, Bernson D, Stopka TJ, Pivovarova E, Ferguson WJ, Rottapel R, Hoskinson R, Wilson D, Evans EA. COVID-19 impact on opioid overdose after jail release in Massachusetts. Drug Alcohol Depend Rep. 2023 Mar; 6:100141.
    View in: PubMed
    Score: 0.914
  3. Evans EA, Pivovarova E, Stopka TJ, Santelices C, Ferguson WJ, Friedmann PD. Uncommon and preventable: Perceptions of diversion of medication for opioid use disorder in jail. J Subst Abuse Treat. 2022 07; 138:108746.
    View in: PubMed
    Score: 0.852
  4. Evans EA, Wilson D, Friedmann PD. Recidivism and mortality after in-jail buprenorphine treatment for opioid use disorder. Drug Alcohol Depend. 2022 02 01; 231:109254.
    View in: PubMed
    Score: 0.846
  5. Michener PS, Evans EA, Ferguson WJ, Friedmann PD. Diffusion of medications for opioid use disorder treatment in jail settings: a convergent mixed methods study of jail staff perspectives. Addict Sci Clin Pract. 2024 Feb 12; 19(1):10.
    View in: PubMed
    Score: 0.244
  6. Matsumoto A, Santelices C, Evans EA, Pivovarova E, Stopka TJ, Ferguson WJ, Friedmann PD. Jail-based reentry programming to support continued treatment with medications for opioid use disorder: Qualitative perspectives and experiences among jail staff in Massachusetts. Int J Drug Policy. 2022 11; 109:103823.
    View in: PubMed
    Score: 0.220
  7. Stopka TJ, Rottapel RE, Ferguson WJ, Pivovarova E, Toro-Mejias LD, Friedmann PD, Evans EA. Medication for opioid use disorder treatment continuity post-release from jail: A qualitative study with community-based treatment providers. Int J Drug Policy. 2022 Dec; 110:103803.
    View in: PubMed
    Score: 0.220
  8. Pivovarova E, Evans EA, Stopka TJ, Santelices C, Ferguson WJ, Friedmann PD. Legislatively mandated implementation of medications for opioid use disorders in jails: A qualitative study of clinical, correctional, and jail administrator perspectives. Drug Alcohol Depend. 2022 05 01; 234:109394.
    View in: PubMed
    Score: 0.214
  9. Evans EA, Stopka TJ, Pivovarova E, Murphy SM, Taxman FS, Ferguson WJ, Bernson D, Santelices C, McCollister KE, Hoskinson R, Lincoln T, Friedmann PD. Massachusetts Justice Community Opioid Innovation Network (MassJCOIN). J Subst Abuse Treat. 2021 09; 128:108275.
    View in: PubMed
    Score: 0.197
  10. Friedmann PD, Abraham A, Evans E, Glass J, Ilgen M, Montgomery L. Editorial: COVID-19 and its impact on SUD treatment. J Subst Abuse Treat. 2020 10; 117:108091.
    View in: PubMed
    Score: 0.191
  11. Bovell-Ammon BJ, Yan S, Dunn D, Evans EA, Friedmann PD, Walley AY, LaRochelle MR. Prison Buprenorphine Implementation and Postrelease Opioid Use Disorder Outcomes. JAMA Netw Open. 2024 Mar 04; 7(3):e242732.
    View in: PubMed
    Score: 0.061
  12. Montgomery L, Friedmann P, Abraham A, Evans E, Glass J, Ilgen M. Editorial: Health equity in substance use disorder treatment. J Subst Abuse Treat. 2020 11; 118:108101.
    View in: PubMed
    Score: 0.048
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.